Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia. The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's Disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard"). For further information, please visit www.Amarantus.com, or connect with the company on Facebook, Twitter, LinkedIn & Google+
PRESS RELEASES & NEWS ARTICLES
Initiating Studies for CLIA Launch at Icon Central Laboratories
September 2nd, 2014 8:00 am
Amarantus BioScience Holdings, Inc. - "Initiating Studies for CLIA Launch at Icon Central Laboratories"
Sept 2, 2014 8:26 a.m.
Amarantus Initiates CLIA Development of Alzheimer's Blood Diagnostic LymPro Test(R) at ICON Central Laboratories
Sept 2, 2014 6:00 a.m.
Amarantus Appoints Iain Ross to Board of Directors
Aug. 29, 2014 7:57 a.m.
Amarantus Reports Second Quarter 2014 Financial Results, Announces Business Update Call
Aug. 27, 2014 9:00 a.m
Amarantus to Present at Upcoming Investor Conferences
Aug. 19, 2014 8:42 A.M.
Amarantus Exercises Option to License Intellectual Property From University of Miami Bascom Palmer Eye Institute for Use of MANF in Retinal Disorders
Aug. 15, 2014 8:11 A.M.
Amarantus BioScience Holdings, Inc. "Preparing Amarantus for the Up-list in 2H-14: Capital Markets Strategy"
Aug. 11, 2014 8:03 a.m.
Amarantus Enters Into Research Collaboration With the Buck Institute for Research on Aging for MANF
Aug. 11, 2014 8:01 A.M. ET
OTC Trading Stock News: Amarantus Biosciences Holdings, Inc. Virtus Oil and Gas Corp, Cannabis Sativa, Inc. Creative Edge Nutrition, Inc. DNA Brands, Inc.
Aug. 5, 2014 8:00 A.M.
Amarantus BioScience Holdings, Inc. - "#C4CT Wrap-up and the Decision to Present Interim LP-002 Data"
Aug. 4, 2014 4:26 P.M..
#C4CT Summit Explored Emerging Theories on Traumatic Brain Injury, Chronic Traumatic Encephalopathy and Possible Links to Alzheimer's Disease
Aug. 4, 2014 8:00 A.M.
Amarantus Announces Positive Top-Line Interim Clinical Data for Alzheimer's Blood Diagnostic LymPro Test(R)
Aug. 1, 2014 9:25 A.M.
Amarantus Acquires Exclusive Option to License Alzheimer's Therapeutic IP of Dr. Thomas Arendt From University of Leipzig
Aug. 1, 2014 8:01 A.M.
SNNLive - Amarantus BioScience Holdings, Inc.
Published on June 21, 2014
SNNLive - Amarantus BioScience Holdings, Inc.
Published on May 21, 2014
Medical Dictionary (some often-used terms in AMBS PRs)
The substania nigra is an area of pigmented cells in the midbrain which is responsible for producing the neurotransmitter dopamine. This section of the brain plays an important role in the control of movement, and it also appears to interact in the process of addiction, as well. If you view a brain in cross-section, the substantia nigra is located in the midbrain, right at the tip of the brainstem.
The striatum is also called the striate body. It includes the caudate nucleus and the lentiform nucleus. The term striatum (striate) refers to the layered appearance of bands of gray matter that course from one of these nuclei to the other and represent the connections between them.
In living tissues, reinnervation describes the process by which post-synaptic neurons form new synapses or increase existing synaptic efficacy in order to compensate for a lack of pre-synaptic input from dead or otherwise dysfunctional pre-synaptic neurons.
Glial cell-derived neurotrophic factor, also known as GDNF is a protein that, in humans, is encoded by the GDNF gene. GDNF is a small protein that potently promotes the survival of many types of neurons.[2
Myocardial infarction (MI) or acute myocardial infarction (AMI), commonly known as a heart attack
Pertinent Terms of Service
A. Is unlawful, threatening, abusive, harassing, defamatory, libelous, vulgar, hateful, deceptive, fraudulent, invasive of another's privacy, tortious, contains explicit or graphic descriptions or accounts of sexual acts (including but not limited to sexual language of a violent or threatening nature directed at another individual or group of individuals), or otherwise violates our rules or policies; This includes signatures as well.
B. Attacks, verbally or otherwise, any other user, the website, any non-public figure, or any agents or employees of iHub; This includes signatures as well.
C. Victimizes, harasses, degrades, or intimidates an individual or group of individuals on the basis of religion, gender, sexual orientation, race, ethnicity, age, or disability; This includes signatures as well.
A reminder, if your post is removed and you think it should be restored go to mailbox, and then click on removed posts, and follow the directions. Post that talk about other members, or other companies violate the TOS. Those posts are routinely deleted. It is easy to talk about AMBS without talking about the posters or in most cases, other companies and products.
Gerald Commissiong, President and CEO, is scheduled to present to investors at the 16th Annual Rodman & Renshaw Healthcare Conference to be held September 8-10, 2014 at the New York Palace Hotel in New York City. The presentation is scheduled for Tuesday, September 9th at 2:30 PM ET and will be web cast live, please visit the Company's IR Events section to participate. Additional information about the conference can be found at http://www.rodm.com/.
Mr. Commissiong is also scheduled to present at the Aegis Capital Healthcare and Technology Conference to be held at the Wynn Las Vegas on September 10-13, 2014. His presentation will take place on Thursday, September 11th at 2:30 PM PT. Conference information may be found at http://www.meetmax.com/sched/event_25932/~public/conference_home.html?event_id=25932.
Amarantus will also be participating in the First Annual Zacks Healthcare Meetup on Monday, September 8th.
Attendees who wish to meet with management one on one may contact the conference organizers or our Investor Relations department at firstname.lastname@example.org.
AMBS expect to complete the agreement with Big Pharma, partner by the end of the summer.
Amarantus BioScience Holdings, Inc.
c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107
c/o ICS Corporate Services SA
29 quai du Mont Blanc
Phone: (408) 737-2734
Fax: (408) 852-4427
Director of Investor Relations
Amarantus BioScience Holdings, Inc
VStock Transfer, LLC
77 Spruce Street, Suite 201
Cedarhurst, NY 11516
Attn: Allison Niccols